OPKO Health, Inc. Announces the Cessation of Alexis Borisy as Member of the Board of Directors and Member of Compensation Committee of the Board
February 09, 2024 at 09:07 pm
Share
On February 9, 2024, Alexis Borisy, a member of the Board of Directors of OPKO Health, Inc. (the Company), and a member of Compensation Committee of the Board, informed the Board that he does not intend to stand for reelection at the Company?s 2024 Annual Meeting of Stockholders. Accordingly, Mr. Borisy?s service as a member of the Board will cease at the Company?s 2024 Annual Meeting of Stockholders scheduled to be held on March 28, 2024, at which time the Board will be reduced to 11 members. Mr. Borisy?s decision not to stand for reelection is not a result of any disagreement with the Company.
OPKO Health, Inc. is a multinational biopharmaceutical and diagnostics company. The Company's diagnostics segment consists of the clinical laboratory operations of BioReference Health, LLC (BioReference), its point-of-care operations. Its pharmaceutical segment consists of the pharmaceutical operations in Chile, Mexico, Ireland, Israel, Spain, Ecuador, France, the United States, and its pharmaceutical research and development operations. Through BioReference, it operates specialized laboratory divisions, such as GenPath (Urology), GenPath (Oncology), and GenPath (Women's Health). It has two commercial stage pharmaceutical products and several pharmaceutical compounds and technologies in various stages of research and development for a range of indications and conditions, including Rayaldee, Rayaldee, Oxyntomodulin, Biologics, NGENLA Somatrogon, and Factor VIIa-CTP. It develops and manufactures specialty active pharmaceutical ingredients (APIs) through FineTech Pharmaceutical, Ltd.